Imatinib for chronic myeloid leukaemia: A NICE mess [1] (multiple letters)

Lancet

Volumn 358, Issue 9296, 2001, Pages 1902-1903

  Rajaratnam, Giri ^a   Edwards, John ^a   O'Brien, Stephen G ^b   Lim, Davin ^c   Muir, Jim ^c  

^a North Staffordshire Health Authority   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c MATER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG EFFICACY; DRUG INDUCED DISEASE; ETHICS; FINANCIAL MANAGEMENT; GASTROINTESTINAL TUMOR; HEALTH CARE; HUMAN; LETTER; MODEL; ORGANIZATION; POPULATION; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL; COST BENEFIT ANALYSIS; ECONOMICS; NOTE; PUBLIC HEALTH; TREATMENT OUTCOME; UNITED KINGDOM;

ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; GREAT BRITAIN; HUMANS; LEUKEMIA, MYELOID, CHRONIC; NATIONAL HEALTH PROGRAMS; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME; FINANCING, GOVERNMENT;

EID: 0035654362     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(01)06901-x     Document Type: Letter

References (1)

1. V Barbour Imatinib for chronic myeloid leukaemia: a NICE mess Lancet 358 2001 1478